Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well glucarpidase works in reducing toxicity in patients
with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the
levels of methotrexate in patients' blood and lead to shorter hospitalizations and a
reduction in toxicities.
Phase:
Early Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
BTG International Inc. National Cancer Institute (NCI) Oregon Health and Science University